Article

Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.

Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Bone Marrow Transplantation (Impact Factor: 3.47). 06/2006; 37(9):857-64. DOI: 10.1038/sj.bmt.1705340
Source: PubMed

ABSTRACT We evaluated the risk factors for infection of 367 consecutive myeloma patients who underwent high-dose melphalan and autologous stem cell transplantation (ASCT). Examination of bone marrow iron stores (BMIS) prior to ASCT was used to evaluate body iron stores. Other variables included age, sex, active smoking, myeloma remission status, severity of mucositis and duration of severe neutropenia post-ASCT (<100 absolute neutrophils counts (ANC)/microl). Median age was 56 years; 61% of patients were males. 140 episodes of severe infections occurred in 116 patients, including bacteremia (73), pneumonia (40), severe colitis (25) and bacteremia with septic shock (two). The infection incidence per 1,000 days at risk was 45.2. Pre-ASCT risk factors for severe infection by univariate analysis were increased BMIS (OR=2.686; 95% CI 1.707-4.226; P<0.0001), smoking (OR=1.565; 95% CI 1.005-2.437; P=0.0474) and male gender (OR=1.624; 95% CI 1.019-2.589; P=0.0414). Increased BMIS (OR=2.716; 95% CI 1.720-4.287; P<0.0001) and smoking (OR=1.714; 95% CI 1.081-2.718; P=0.022) remained significant by multivariate analysis. Duration of ANC <100 micro/l (OR=1.129; 95% CI 1.039-1.226; P=0.0069 and OR=1.127; 95% CI 1.038-1.224; P=0.0045 by both univariate and multivariate analysis, respectively) was the only post-ASCT risk factor for infection. Increased pre-transplant BMIS and smoking are significant predictors of severe infection after myeloablative chemotherapy followed by ASCT in myeloma patients.

0 Bookmarks
 · 
90 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This is the first prospective study of deferasirox in adult allogeneic hematopoietic stem cell transplant recipients with transfusional iron overload in hematologic malignancies. Patients at least 6 months post-transplant were treated with deferasirox at a starting dose of 10 mg/kg/day for 52 weeks or until serum ferritin was ≤400 ng/mL on two consecutive determinations. Thirty patients were enrolled and 22 patients completed the study. A significant reduction from baseline in median serum ferritin and in liver iron concentration at 52 weeks was observed in the overall population (1440 to 755.5 ng/mL, P=0.002; and 14.5 to 4.6 mg Fe/g dw, P=0.0007, respectively). Serum ferritin reduction in patients without deferasirox discontinuation was significantly greater than was found in those who prematurely discontinued the treatment (1541 to 581 ng/mL versus 1416 to 1486 ng/mL, P=0.008). Drug-related adverse events, reported in 17 patients (56.7%), were mostly mild to moderate in severity. There were no drug-related serious adverse events. Increase in serum creatinine >33% compared to baseline and greater than the upper limit of normal on two consecutive visits occurred in 12 patients (40.0%). Increase in alanine aminotransferase exceeding 10 x upper limit of normal occurred in 2 patients (6.7%) with active graft versus host disease, both of which resolved. In this prospective study, deferasirox provided significant reduction in serum ferritin and liver iron concentration over one year of treatment in allogeneic hematopoietic stem cell transplant recipients with iron overload. Additionally, the majority of adverse events related to deferasirox were mild or moderate in severity.
    Haematologica 07/2014; DOI:10.3324/haematol.2014.105908 · 5.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Blood stream infection (BSI) is the most common infectious complication of hematopoietic stem cell transplantation (HSCT) and can cause substantial morbidity and mortality. Identification of risk factors for BSI might be helpful in efforts to reduce transplant-related death. This study analyzed the incidence of BSI and risk factors for BSI after transplantation in pediatric patients with aplastic anemia (AA). BSI occurred in 39 of 351 patients with AA (11.1%). Median onset of BSI was 8 days after transplantation (0 to 92 days). The 5-year overall survival rate was lower in patients with BSI (63.32±7.90%) than in patients without BSI (93.35±1.44%, p<0.0001). Univariate analysis showed that variables associated with BSI included history of immunosuppressive therapy with anti-thymocyte globulin, transplantation from unrelated donors, frequent blood transfusion before transplantation, major or major+minor mismatch of ABO blood type, graft versus host disease prophylaxis without cyclosporine and with tacrolimus, and long interval from diagnosis to transplantation. In these factors, long interval from diagnosis to transplantation was the only statistical significant factor for BSI using multivariate analysis. In patients who underwent HSCT from related donors, age ≥ 14 years at transplantation was risk factor of BSI. By contrast, history of immunosuppressive therapy with ATG, frequent blood transfusion before transplantation, graft failure and major or major+minor mismatch of ABO blood type were risk factors of BSI in patients who underwent HSCT from unrelated donors. Since the overall 5-year survival rate without BSI was over 90%, even in patients who were transplanted from an unrelated donor, control of BSI is very important for success of HSCT in patients with pediatric AA.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 04/2014; DOI:10.1016/j.bbmt.2014.04.006 · 3.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tobacco use is a risk factor for adverse outcomes among hematopoietic SCT (HSCT) patients. Accurate identification of tobacco use offers a vital opportunity to treat this risk factor. The current study compared self-reported tobacco use status with serum cotinine levels among HSCT patients at the time of pre-transplant evaluation. A total of 444 participants completed both assessments; 44 participants (9.9%) were classified as tobacco users with serum cotinine concentrations >2 ng/mL vs 29 with self-reporting. Sensitivity and specificity of self-reporting were 65.9% and 100%, respectively. Positive and negative predictive values were 100% and 96.4%, respectively. Comparing tobacco use documented in the medical record with cotinine, sensitivity and specificity were 51.2% and 99.2%, respectively. Factors associated with tobacco use were male gender, single relationship status, less education and younger age. In summary, utilization of serum cotinine assays increased detection of tobacco use cases >50% over self-reporting. Results are discussed in the context of translation to care, including clinical and ethical implications, and current tobacco use treatment guidelines. When cotinine assays are not available, self-reporting of any tobacco use in the year before HSCT should trigger brief advice and cessation or relapse prevention counseling.Bone Marrow Transplantation advance online publication, 14 April 2014; doi:10.1038/bmt.2014.70.
    Bone marrow transplantation 04/2014; 49(7). DOI:10.1038/bmt.2014.70 · 3.00 Impact Factor

Preview

Download
0 Downloads
Available from

Similar Publications